₹100 tablets to prevent cancer recurrence? Here's what Tata Memorial Hospital's big discovery states

The Tata Institute in Mumbai has made a groundbreaking discovery to prevent cancer recurrence. Their ten years of research has formulated a tablet designed to thwart cancer re-occurrence in patients while notably mitigating the adverse effects associated with treatments such as radiation and chemotherapy.

The research found that dying cancer cells release chromatin particles

Speaking with NDTV, senior cancer surgeon at Tata Memorial Hospital, Dr Rajendra Badve explained how the research was done on rats. Rats were injected with cancerous cells leading to formation of tumours in their body. The rats were then treated with radiation therapy, surgery and cherotherapy. The research found that dying cancer cells release chromatin particles which travel to healthy blood cells making them cancerous.

To prevent this, the scientists provided pro-oxidant tablets consisting of resveratrol and copper (R+Cu) to the rats. The R+Cu tablets generate oxygen radicals, which destroy these chromatin particles.

When taken orally, the R+Cu tablets help in preventing the spread of these chromatin particles and reduces chemotherapy toxicity.

Dubbed as the 'magic of R+Cu', the tablets are expected to reduce the side effects of cancer treatment by about 50% and is effective in preventing cancer recurrence by around 30%. It is promising in treating pancreas, lungs, and oral cavity cancers.

Approval pending from the FSSAI

The tablet is presently pending approval from the Food Safety and Standards Authority of India (FSSAI). After being approved, they are expected to be available in stores around June or July at just Rs 100. Trials on humans is also under trial and will take approximately five more years to be complete.

Also watch: Sidhu Moosewala's mom conceives at 58 through IVF; doctor shares how safe post menopausal pregnancy is